"Validated" does not automatically mean inspection-ready. Readiness is demonstrated when decisions are traceable, governance is clear and evidence can be produced quickly and confidently under scrutiny.
Inspection readiness is not about volume of documentation. It is a state where intended use is clear, risk decisions are explainable, operational controls are active and evidence is retrievable without rework.
Inspectors expect answers that remain consistent across documentation, system behaviour and verbal explanation. Inconsistencies are the most common trigger for deeper sampling.
Validation was treated as a project outcome rather than a continuous state. Current use and configuration have drifted from what was validated.
Documents are there, but locating, assembling and presenting them under inspection pressure takes too long and produces an incoherent picture.
Supplier releases are acknowledged but impact assessment, testing decisions and rationale are not consistently evidenced.
Defined in the SOP. Not producing outputs with actions, owners and completion evidence that demonstrate active, continuous control.
SOPs, system configuration and actual team behaviour tell different stories. Inconsistency is a red flag for inspectors.
The path from intended use through risk to testing to release is not explainable end-to-end. Individual documents exist; a connected story does not.
Based on a genuine engagement. Details are anonymised, and in some cases composited, to protect client confidentiality.
A specialist pharmaceutical manufacturer had a confirmed FDA pre-approval inspection date for a new product. QA leadership needed an objective, external assessment of validation programme readiness across all GxP computerised systems in scope, with sufficient time to remediate before the inspection.
Despite an active validation programme, there was no consolidated inspection narrative. Individual system records existed in isolation and had never been reviewed as a programme. There was no way to know how the CSV programme would present to an FDA investigator until someone looked at it the way an investigator would.
A structured mock inspection was conducted, covering CSV programme governance, data integrity controls, audit trail configuration, Part 11 applicability, supplier oversight and system-specific validation records. Findings were risk-ranked and a targeted remediation plan was produced and executed within the available six-week window before the inspection date.
The FDA pre-approval inspection completed with no CSV observations. The site received its approval recommendation on schedule. QA leadership described the mock inspection process as the single most valuable preparation activity undertaken.
Mention your inspection timeline when you book. We will prioritise accordingly and build from the gaps that matter most.